Shorting the market.

With more and more confirmatory data emerging on the safety and efficacy of prostate ultra-hypofractionation, it’s no surprise that many are opting for a 5-day option over a 5-week one. This large NCDB analysis demonstrates the proportion of patients with prostate cancer opting for this definitive treatment approach more than doubled from 3% to 7% just between 2010 and 2015, most commonly at academic centers and / or in urban areas. | Mahase, JAMA Netw Open 2020